3 months 6 months 12 months 18 months Response CHR PCyR CCyR MMR Suboptimal response <CHR <PCyR (≥35% Ph1 positive metaphases) <CCyR <MMR Failure No hematological response, stable disease, or disease progression <CHR or no CyR (≥95% Ph1 positive metaphases) <PCyR (≥35% Ph1 positive metaphases) <CCyR Failure At any time: loss of CHR, or loss of CCyR, or Abl kinase Mutation

Table 2: NCCN and European LeukemiaNet criteria for remission, suboptimal response and failure for previously untreated chronic-phase CML patients on standard dose of imatinib.